SCHEMBL1132250

SCHEMBL1132250

COC(=O)c1cc2c(Oc3ccc([N+](=O)[O-])cc3Cl)ccnc2cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 7/20 0.54
KDR P35968 7/20 0.54
AXL P30530 3/20 0.50
MET P08581 2/20 0.50
MERTK Q12866 1/20 0.50
SRC P12931 4/20 0.46
TGFBR1 P36897 4/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
NPC1 O15118 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21198916 0.88 KDR (0.52) PDGFRAKDRAXLMETMERTK
SCHEMBL1132613 0.88 KDR (0.54) PDGFRAKDRAXLMETMERTK
SCHEMBL1895689 0.86 KDR (0.71) PDGFRAKDRAXLMETMERTK
SCHEMBL1132608 0.84 AXL (0.53) PDGFRAKDRAXLMETMERTK
SCHEMBL21198888 0.83 PDGFRA (0.55) PDGFRAKDRAXLMETMERTK
SCHEMBL19957375 0.82 KDR (0.53) PDGFRAKDRAXLMETSRC
SCHEMBL1893379 0.82 KDR (0.53) PDGFRAKDRAXLMETTDP1
SCHEMBL21198895 0.80 PDGFRA (0.51) PDGFRAKDRAXLMETMERTK
SCHEMBL1133096 0.79 AXL (0.59) PDGFRAKDRAXLMETMERTK
SCHEMBL1133098 0.79 AXL (0.59) PDGFRAKDRAXLMETMERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2287155-B1 ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2013-07-17 EP disclosed
US-8304427-B2 Acylthiourea compound or salt thereof, and use thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2012-11-06 US disclosed
EP-2287155-A1 ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE OF THE COMPOUND OR THE SALT Taiho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed
US-20110034439-A1 ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034439-A1 ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF MET, HGF, STAT6 PDGFRA 201/4885KDR 296/4885AXL 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.